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Crystal Structure of Human Thymidine Phosphorylase
in Complex with a Small Molecule Inhibitor
led Pugmire and Ealick to propose a catalytic mecha-
nism for this family of enzymes in which the pyrimidine
nucleoside is bound in a high-energy conformation
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Mark S.B. McAlister, Eileen J. McCall, causing the weakening of the glycosidic bond. The gly-
cosidic bond is weakened further by flow of electronsHelen H.J. McMiken, Dougie S. Paterson,
David Timms, Julie A. Tucker, and Richard A. Pauptit* from O-5 of the ribose moiety to the pyrimidine ring,
while the phosphate ion is positioned to attack the C-1AstraZeneca
Alderley Park position of the ribose ring to yield 2-dR-1-P and the free
pyrimidine base (Pugmire and Ealick, 1998, 2002) (FigureMacclesfield, Cheshire SK10 4TG
United Kingdom 1). HTP is able to transfer the deoxyribosyl moiety from
one pyrimidine base to another thus playing an addi-
tional vital role in base/nucleotide salvage (Zimmerman
and Seidenberg, 1964a, 1964b).Summary
HTP is now understood to be identical to PD-ECGF,
which is an angiogenic activity identified in platelet ly-Human thymidine phosphorylase (HTP), also known
sates (Miyazono et al., 1987), and to gliostatin whichas platelet-derived endothelial cell growth factor (PD-
has important physiological roles in neuronal and glialECGF), is overexpressed in certain solid tumors where
development (Asai et al., 1992). The activity of HTP cor-it is linked to poor prognosis. HTP expression is uti-
relates with hypoxia and the induction of angiogenesislized for certain chemotherapeutic strategies and is
in a number of malignant and hyperproliferative diseasealso thought to play a role in tumor angiogenesis. We
states. HTP overexpression and elevated enzyme activ-determined the structure of HTP bound to the small
ity have been found in the plasma of cancer patientsmolecule inhibitor 5-chloro-6-[1-(2-iminopyrrolidinyl)
(Pauly et al., 1977), and HTP expression has been linkedmethyl] uracil hydrochloride (TPI). The inhibitor ap-
with the invasive/metastatic capacity of gastric (Maedapears to mimic the substrate transition state, which
et al., 1996; Takebayashi et al., 1996b), bladder (Mizutanimay help explain the potency of this inhibitor and the
et al., 1997; O’Brien et al., 1995, 1996), and colorectalcatalytic mechanism of pyrimidine nucleotide phos-
(Takebayashi et al., 1996a) tumors. HTP activity is alsophorylases (PYNPs). Further, we have confirmed the
elevated in ovarian (Reynolds et al., 1994), oesophageal,validity of the HTP structure as a template for struc-
and pancreatic cancers (Takebayashi et al., 1996a), andture-based drug design by predicting binding affinities
has been shown to be associated with a more aggres-for TPI and other known HTP inhibitors using in silico
sive phenotype in nonsmall cell lung cancer node-nega-docking techniques. This work provides the first struc-
tive disease (Fox et al., 1996). HTP overexpression hastural insight into the binding mode of any inhibitor
been implicated in other angioproliferative disorders,to this important drug target and forms the basis for
including rheumatoid arthritis (Takeuchi et al., 1994),designing novel inhibitors for use in anticancer therapy.
psoriasis (Creamer et al., 1997), and hyperproliferation
of the vasa vasorum in artherosclerosis (Ignatescu et
Introduction al., 1999). The in vivo angiogenic activity associated with
HTP is thought to be mediated by dephosphorylated
HTP (EC 2.4.2.4) has a primary catabolic role in pyrimi- 2-deoxyribose and although the mechanism is unclear
dine nucleoside metabolism, catalyzing the reversible it does require the enzyme activity of HTP (Miyadera et
phosphorolysis of thymidine, deoxyuridine, and their an- al., 1995; Moghaddam et al., 1995; Sumizawa et al.,
alogs (except deoxycytidine) to their respective bases 1993). The activity of HTP inactivates certain chemother-
and 2-deoxyribose-1-phosphate (2-dR-1-P) (Krenitsky apeutic agents such as TFT (trifluorothymidine) (Fuku-
et al., 1981). HTP is a member of the PYNP family which shima et al., 2000) and can also be used to catalyze the
in higher species consists of two PYNPs, TP and uridine conversion of prodrugs such as tegafur (1-(tetrahydro-
phosphorylase (UP), and in lower organisms consists of 2-furanyl)-5-fluorouracil) and capecitabine (N4-pentylox-
only one PYNP with dual (TP and UP) activity (Krenitsky ycarbonyl-5-deoxy-5-fluorocytidine) to anticancer nu-
et al., 1965; Pugmire and Ealick, 2002). Kinetic studies cleotides which interfere with DNA replication (Patterson
using E. coli TP (EcTP) and rabbit muscle TP have shown et al., 1995; Miwa et al., 1998). Whereas the latter type
that the enzyme follows a sequential mechanism whereby of therapy would be incompatible with HTP inhibition,
phosphate is the first substrate to bind and 2-dR-1-P inhibitors of HTP may be used to provide alternative
is the last product to leave (Krenitsky, 1968; Schwartz, agents to control angiogenesis and in combination with
1971). These results are supported by evidence that TFT therapy. These alternative approaches would prove
the enzyme is stabilized by phosphate and 2-dR-1-P, especially attractive in cases where primary fluoropyri-
but not by thymidine or thymine (Krenitsky and Tuttle, midine therapy has failed.
1982). Structural studies on B. stearothermophilus PYNP Recently, a number of HTP inhibitors have been re-
(BsPYNP), bound to pseudouridine and phosphate, have ported, the most potent of which is TPI (5-chloro-6-[1-
(2-iminopyrrolidinyl) methyl] uracil hydrochloride) with
Ki  20 nM. TPI causes a substantial reduction in tumor*Correspondence: richard.pauptit@astrazeneca.com
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Figure 1. Reaction Catalyzed by HTP
growth when given continuously to mice carrying HTP which crystallized. Whereas we had initially assumed
we had removed a portion of the C-terminal domain,overexpressing tumors by increasing the proportion of
apoptotic cells and possibly also inhibiting angiogenesis remote from the active site, analysis of the crystals by
SDS-PAGE showed the crystallized product included(Matsushita et al., 1999). The combination of TFT and
TPI in a 1:0.5 molar ratio (TAS-102) is currently tested two fragments: 12–408 and 411–482. Functional assays
carried out on the proteolyzed HTP show that it pos-in phase I trials and can be administered orally (Thomas
et al., 2002). Less potent HTP inhibitors have been de- sesses the same degree of activity as full-length HTP
toward its substrate (data not shown).signed using models of HTP based on the structure of
EcTP or BsPYNP (Cole et al., 2003; Price et al., 2003). Crystals of HTP belong to the space group C2 and
the asymmetric unit contains a single HTP protomer.Both bacterial enzymes (90 kDa) possess around 40%
sequence identity with HTP and, like the larger mamma- The three-dimensional structure of HTP was determined
by the molecular replacement method, using the crystallian TPs (110 kDa), are homodimers (Desgranges et
al., 1981; Kraut and Yamada, 1971; Pugmire and Ealick, structure of BsPYNP as the search model (see Experi-
mental Procedures). The structure was refined to an R1998; Schwartz, 1978). Each subunit of the bacterial
enzymes consists of a small -helical domain ( domain) factor of 18.9% and an Rfree of 25.8% (Table 1). The final
Fo-Fc electron density for the bound TPI is shown inand a large mixed -helical and  sheet domain (/
domain) separated by a large cleft containing the sub- Figure 2. Recombinant HTP spans residues 12–482;
however, the proteolytic treatment removed residuesstrate binding site (Pugmire and Ealick, 1998; Walter et
al., 1990). Movement of the two domains allows for an 409 and 410 causing the remainder of the loop (residues
407–408 and 411–414) to become disordered. No elec-open (empty) or closed (substrate-bound) conformation
of the enzyme (Pugmire and Ealick, 1998; Pugmire et tron density was observed for residues 12–32 (N termi-
nus), 238–239, and 481–482 (C terminus). The structureal., 1998).
Here, we report the crystal structure of HTP in com- of HTP contains one molecule of TPI in the active site.
plex with TPI in an active (closed) conformation. Since
this is the first structure of any PYNP family member Structure of HTP and Comparison to Other PYNPs
bound to an inhibitor, it will provide the basis for further The HTP protomer (Figure 3A) has a similar fold to that
structure-based drug design studies with the aim of reported for EcTP and BsPYNP (Pugmire and Ealick,
increasing current inhibitor potency and specificity, or 1998; Walter et al., 1990) and comprises an  domain
developing new anticancer drug candidates. and a mixed/domain connected by three polypeptide
loops (Figure 3B). The  domain consists of six  helices
(1–4 and 8–9), and the / domain consists of aResults and Discussion
central mixed  sheet (1–5, 13) surrounded by 
helices (5–7 and 10–16) and two small antiparallelHTP Proteolysis and Structure Determination
Crystals of recombinant HTP which diffract to 3.5 A˚ have  sheets (consisting of strands 6, 7, 9, and 11, and
8, 10, and 12 respectively) flanked by two  helicesbeen reported (Spraggon et al., 1993). In our hands,
however, crystallization trials with HTP (residues 12– (17 and 18). The three loops act as a hinge allowing
the two domains to move between the open (inactive)482) have for many years failed to produce diffraction-
grade crystals. Sequence alignments (data not shown) and closed (active) conformations, bringing together the
active site residues (Pugmire and Ealick, 1998; Pugmireof HTP with EcTP and BsPYNP show a glycine-rich
N-terminal extension of 32 residues in HTP which is et al., 1998). The main structural differences between
HTP, EcTP, and BsPYNP are in the / domain whereassumed to lack defined secondary structure. Since dis-
ordered N- or C termini of proteins could conceivably HTP has an additional helix (15), an extra turn in 16,
and a more extended C-terminal region. The small anti-lead to crystallization difficulties, limited proteolysis was
performed with a range of proteases in an attempt to parallel  sheet (8, 10, and 12) is present in HTP and
BsPYNP but not in EcTP.define a minimal domain more amenable to successful
crystallization. This yielded a product from which resi- An HTP dimer is generated from the single protomer
that constitutes the asymmetric unit by rotation aboutdues 409 and 410 had been cleaved, as shown by Edman
sequencing and electrospray mass spectrometry, and the crystallographic 2-fold axis (Figure 3C). The core of
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latch, holding the  and / domains together. ResiduesTable 1. Data Collection, Refinement Statistics, and Model
A366, K367, and K368 (in BsPYNP) from the tip of thisQuality
loop make contacts with the opposing molecule in the
TP-TPI Complex dimer. It has been proposed that dimer interactions
Resolution range (A˚) 91.3–2.1 around this loop have a functional role in closing the
Spacegroup C2 active site cleft (Pugmire and Ealick, 1998). Residues
Z 4 S409 and R410 (corresponding to A366 and K367 in
Cell dimensions
BsPYNP) are not present in the HTP that we crystallizeda 70.0 A˚
and consequently this loop is disordered in our struc-b 66.1 A˚
ture. However, HTP still adopts a closed conformationc 96.9 A˚
 106.5 (see below) and the species crystallized has been shown
Wavelength (A˚) 0.9780 to be fully active. Thus, for HTP, this region is not essen-
Observed reflections 32,998 tial for the formation of an active enzyme.
Unique reflections 15,827 Structural studies on BsPYNP (Pugmire and Ealick,
Highest resolution shell (A˚) 2.21-2.11
1998) suggest that binding of phosphate results in theRedundancy 2.1 (1.3)a
formation of a key hydrogen bond between residuesI/(I) 15.5 (1.8)
H116 and G205 (corresponding to H150 and A239 ofCompleteness (%) 63.7 (11.2)
Rmerge (%) 3.0 (19.3) HTP), causing an 8 rotation of the / domain with
Rwork (%) 18.8 (34.8) respect to the  domain compared to the structure in
Rfreeb (%) 25.8 (57.7) the absence of phosphate. Subsequent binding of the
Rms bond lengths (A˚) 0.015
pyrimidine base would be responsible for an additionalRms bond angles () 1.5
20 rotation to form the fully closed active site (PugmireNumber of nonhydrogen atoms
and Ealick, 1998, 2002). Phosphate is absent from theProtein 3,214
Inhibitor 16 catalytic site in our structure, A239 is disordered, and
Water 75 therefore no hydrogen bond is observed between H150
Mean temperature factors (A˚2) and A239. Our HTP structure appears to be in the active
Protein 23.9 (closed) conformation. Alignment of the  domain ofInhibitor 19.9
HTP with the corresponding  domains of EcTP andRamachandran plotc (%)
BsPYNP gave rms deviations of 0.82 and 0.67 A˚, respec-Residues in most favored regions 94.5
Residues in additional allowed regions 5.5 tively, for 100 equivalent C atoms. Alignment of the
Residues in disallowed regions 0 HTP / domain with the corresponding / domains
of EcTP and BsPYNP gave rms deviations of 1.94 anda Values in parentheses correspond to the high resolution shell.
1.46 A˚, respectively, over 282 C atoms. However, anb Rfree was calculated against 5.4% of the complete dataset excluded
from refinement. alignment of the entire HTP protomer with the EcTP and
c Statistics obtained from PROCHECK (Laskowski et al., 1993). BsPYNP structures gave rms deviations of 3.55 and
1.71 A˚, respectively, over 383 C atoms. While the indi-
vidual domains superpose well, the overall structural
the dimer interface is analogous to that of the BsPYNP similarity between HTP and EcTP is less than that for
structure and consists of a coiled coil formed by helices HTP and BsPYNP. By analogy to BsPYNP, HTP is in
3 from each monomer. Also, helix 1 of one monomer the active (closed) conformation (Figure 4). Thus, the
packs against the loop connecting helices 8 and 9 of presence of the inhibitor TPI alone, without phosphate,
the second monomer. In the BsPYNP structure, residues is sufficient to cause closure of the  and / domains
364–371, which correspond to the clipped loop of HTP, to form the active conformation.
The structure of BsPYNP contains a metal binding siteextend across the active site cleft and appear to act as a
Figure 2. Electron Density Corresponding to TPI
Stereo view of the final 2.1 A˚ Fo-Fc omit map to within 2 A˚ of the inhibitor molecule contoured at 3.0 (cyan). Nitrogen atoms are blue; oxygen
atoms, red; chlorine atom, lime green; carbon atoms and bonds, light purple. All molecular graphics were produced using Bobscript (Esnouf,
1999) and Raster3D (Merrit and Murphy, 2003) except Figure 7, which was produced using PyMOL (DeLano, 2002).
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Figure 4. Fold Comparison of HTP
Comparison of the fold of HTP with EcTP and BsPYNP. The three molecules are shown in the same orientation, and colored red to blue (N
terminus to C terminus). Bound pseudouridine (light purple) and phosphate (red) in the BsPYNP structure and TPI (light purple) in the HTP
structure are shown as cpk models. Arrows indicate domain movement giving the active conformation of the enzyme.
adjacent to the phosphate binding site. This unidentified domain and L148 and V241 of the/domain, and forces
the 2-oxo, 3-amido, and 4-oxo groups of the 5-chlo-penta-coordinate metal interacts with the backbone car-
bonyl oxygen atoms of residues L243, A246, and G88, rouracil moiety closer to their interacting partners rela-
tive to uracil. The C2 of V241 lies 4.4 A˚ from the chlorine,and the side chains of E255 and T90 (BsPYNP). In the
HTP structure, there is no metal ion present, but the N indicative of good van der Waals interactions between
the two atoms. By analogy, the methyl group of thymineatom of K124 (which corresponds to T90 of BsPYNP)
adopts a position similar to the BsPYNP metal ion and would occupy the same position as the chlorine and
would make similar interactions with V241. Uracil, how-interacts with the equivalent residues, possibly fulfilling
the same structural role. ever, lacks a substituent at this position making the
distance between the 5 position and the C2 of V241
approximately 6.0 A˚, creating a hydrophobic cavity. In-Inhibitor Binding, Specificity and Insights
terestingly, of the four residues which form the hy-into the Catalytic Mechanism of HTP
drophobic pocket in HTP, only V241 is not conservedThe HTP active site may be described as having two
in BsPYNP: it corresponds to F207. In the bacterial struc-components, each interacting with one part of the TPI
ture, the distance between the 5 position of uracil andmolecule. The first component of the active site is
the C	2 of F207 is 3.9 A˚, consistent with good van derformed by residues from the  domain and H116 from
Waals interactions between these atoms. Binding of thy-the / domain, which interact with the 5-chlorouracil
mine would result in steric clashes unless the phenylmoiety. The second component of the active site, which
ring of F207 were rotated by 90 around the C-C bondinteracts with the 2-iminopyrrolidinyl moiety, is formed
to accommodate the thymine methyl group at the 5by S117 from the / domain and a network of water
position. Such rotation of the phenyl ring around themolecules which occupy the phosphate binding site
C-C bond may allow BsPYNP to accept both uracil(Figure 5A).
and thymine as substrates, without the need for exten-The 5-chlorouracil of TPI makes strong hydrogen-
sive structural rearrangement of the active site. Thisbonding interactions with R202, S217, K221, and H116
suggests the F207 side chain in BsPYNP may be less(Figures 5A and 5B). These residues are conserved in
discriminating than V241 in HTP. Whereas the basis forthe BsPYNP structure (R168, S183, K187, and H82 re-
specificity has been ascribed to the high affinity of HTPspectively) and, with the exception of H82 (H116 in HTP),
for the 2-deoxyribose moiety of the thymidine substrateform a similar hydrogen-bonding network with the uracil
(Pugmire and Ealick, 2002), there may also be a contribu-moiety of the substrate analog pseudouridine (Figure
tion from V241. Unfortunately, the structure of HTP com-5C). The number of hydrogen bonds between BsPYNP
plexed with TPI offers no direct insights as to the basisand the uracil ring is lower than between HTP and TPI,
of specific interactions between HTP and the thymidineand the equivalent distances are longer, consistent with
2-deoxyribose moiety.the tighter binding of TPI to HTP. Another contribution
The 2-iminopyrrolidinyl moiety of TPI makes two hy-to the tight interactions between HTP and the 5-chlo-
drogen bonds, one to the carbonyl oxygen of S117 androuracil of TPI is the chlorine atom, which is held in a
hydrophobic pocket formed by V208 and I214 of the  one to a water molecule (Figures 5A and 5B). The posi-
Figure 3. Structure of HTP
(A) Stereo view of the HTP monomer showing the main-chain trace of the  domain (cyan), the hinge regions (green), and the mixed /
domain (brown). TPI (light purple) is shown as a cpk model in the active site situated between the  and / domains.
(B) Topology diagram of HTP color coded in the same manner as in (A).
(C) Stereo view of the HTP dimer generated by applying 2-fold crystallographic symmetry to the monomer. HTP monomers are colored cyan
and brown and TPI (light purple) is shown as a cpk model. The position of the proteolytically cleaved loop is indicated by an arrow.
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tively charged character of the 2-iminopyrrolidine may
mimic the oxocarbenium ion-like transition state pro-
posed for thymidine phosphorolysis (Figure 1). This sug-
gests an orientation for the ribose moiety of thymidine
which is rotated by approximately 180 with respect
to previous models (Pugmire and Ealick, 2002). Water
molecules W1 and W2 in HTP (Figures 5A and 5B) mimic
the phosphate oxygen atoms in the BsPYNP structure,
suggesting that these oxygen positions could be rele-
vant and the orientation of the phosphate during cataly-
sis could be similar to that observed in the BsPYNP
crystal structure (Figure 5A). The role of H116, which is
absolutely conserved in the PYNP family, has been the
subject of some debate. It is believed to be involved in
either stabilizing the transition state during catalysis or
in donating a proton to the N-1 of the pyrimidine ring
following glycosidic cleavage (Figure 1). Given that the
pKa of TPI has been measured at 6.05 (our unpublished
data), it is likely that at the pH of crystallization (pH
6.5) the 1-amido group of 5-chlorouracil is anionic and
makes a hydrogen bond with the protonated N	2 of
H116, and N
2 of H116 serves as the hydrogen-bond
acceptor for N of K222. The side chains of both D114
and E225 are positioned within hydrogen-bonding dis-
tance of each other and of K222 in an unusual arrange-
ment (Figure 5A), suggesting this triad forms a proton-
shuttling mechanism whose role is to deliver a proton to
H116. Catalysis would therefore proceed as previously
described followed by protonation of the pyrimidine ring
at the 1-amido position by H116 via the proton shuttle.
Thus, the structure provides evidence for the role of
H116 as the proton donor during thymidine phosphorol-
ysis. In addition, the resemblance of TPI to the zwitter-
ionic transition state during thymidine phosphorolysis
may help explain its high potency.
Figure 6. Structures of HTP Inhibitors Used in Docking Studies
(A) View of the HTP active site color coded and labeled in the same
Implications for Drug Design manner as in Figure 5A showing the superposed docked TPI mole-
cule (yellow). (B) TPI. (C) Compound II, 6-amino-5-bromouracilIn order to establish whether the HTP structure could
(Langen et al., 1967). (D) Compound III, 5-chloro-6-[(2-nitroimidazol-provide the basis for in silico-based drug design, calcu-
1-yl) methyl] uracil (Cole et al., 2003). (E) Compound IV, N-(2,4-dioxo-lations were carried out in an attempt to predict binding
1,2,3,4-tertahydrothieno[3,2-d] pyrimidin-7-yl) guanidine (Price etaffinities for TPI and other known HTP inhibitors. Dock-
al., 2003).
ing TPI into the HTP active site using GLIDE (Eldridge
et al., 1997) yielded a bound position for the inhibitor in
substantial agreement with experiment (rms deviation range of chemical features and affinities were also
docked using GLIDE and their binding energies esti-0.42 A˚ for the nonhydrogen atoms) (Figure 6A). The ionic
status of TPI on binding to the enzyme was investigated mated using the same electrostatic protocol as for TPI.
For these ligands, experimental values of pKa were un-using a binding energy calculation based on Poisson-
Boltzmann electrostatics (Grant et al., 2001). Calcula- available and these were estimated using ACD software
(Advanced Chemistry Development, http://www.acdlabs.tions for the TPI binding mode found by experiment
indicate that the inhibitor binds as the zwitterion (Table com), thus allowing corrected estimates of the binding
constants (Kcorr) to be made. In the case of ligands (II) and2). Three further ligands (Figure 6B) exhibiting a diverse
Figure 5. Active Site
(A) Stereo view of the HTP active site highlighting important interactions. No phosphate is present in HTP, but the position of the phosphate
in the BsPYNP crystal structure is indicated. Nitrogen atoms are blue; oxygen atoms, red; chlorine atom, lime green; phosphate atom, lavender;
carbon atoms and bonds, light purple (inhibitor) and white (protein). Residues which form direct interactions with the inhibitor have their labels
colored light purple and residues which form the hydrophobic pocket around the chlorine atom have their labels colored green. Other residues
and selected water molecules are labeled in black.
(B) Schematic representation of the HTP active site highlighting important interactions. The ring positions of the 5-chlorouracil moiety are
numbered and hydrogen-bonding distances (A˚) are labeled in blue.
(C) Schematic representation of the BsPYNP active site highlighting important interactions. The ring positions of the uracil moiety are numbered
and hydrogen-bonding distances (A˚) are labeled in blue.
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of phosphate. The HTP structure provides a frameworkTable 2. Docking and Scoring Results for Some HTP Ligands
including many replaceable water molecules, which of-
Compound pKaa Kcalc Kcorrb IC50c fers a design opportunity for further developing existing
TPI cation Inactived Inactived inhibitors or to design novel inhibitors (Figure 7).
TPI zwitterion 6.1 (6.9) 345 nM 360 nM 5–20 nM
II neutral 74 mM 111 mM Experimental Procedures
II anion (7.1) 0.375 M 0.6 M 1.6 M
III neutral Inactived Inactived Sample Preparation and Crystallization
III anion (7.3) 6.0 M 10.8 M 21.7 M HTP was expressed in E. coli from plasmid pMOAL-10T (Moghad-
IV cation Inactived Inactived dam and Bicknell, 1992). The plasmid encodes a product consisting
IV zwitterion (9.5) 1.85 M 235 M 76 M of glutathione S-transferase (GST) fused to HTP residues 12–482
(based on Swissprot accession number P19971) via a thrombin-a Values in parentheses were calculated using ACD software (Ad-
cleavable linker. Cells were induced overnight at 15C with 0.1 mMvanced Chemistry Development, http://www.acdlabs.com).
IPTG to maximize soluble accumulation, harvested, and lysed inb Kcorr is the corrected value of Kcalc to account for the fraction of
buffer A (20 mM Tris/HCl, pH 7.4, 100 mM NaCl, 5 mM DTT) by high-the binding form of the compound that would be present in the
pressure homogenization. Cell debris were removed by centrifuga-experimental assay solution.
tion and the lysate supernatant loaded onto a glutathione-sepharosec Experimental IC50 data were taken from (Cole et al., 2003) (TPI,
column equilibrated with buffer A. The column was washed with atcompound II, and compound III) and from (Price et al., 2003) (TPI
least 10 vol of buffer A prior to eluting the product with buffer Aand compound IV).
containing 20 mM reduced glutathione. The product was incubatedd As interpreted from positive G.
for 4 hr at 37C with thrombin (10 U/mg fusion protein) and separated
from the cleaved GST by size-exclusion chromatography on a
Superdex 75 column equilibrated with buffer B (20 mM Tris/HCl,
pH 7.5, 150 mM NaCl, 1 mM DTT). HTP was subjected to limited(III), the anions would appear to be the active entities. For
proteolysis by trypsin (1:100 w/w; 40 min at 37C) followed by addi-ligand (IV), as for TPI, it would appear the zwitterion is
tion of 1 mM phenylmethyl sulphonyl fluoride. Proteolyzed HTP wasbound and the poorer affinity relates to the higher pKa
loaded onto a Superdex 75 column equilibrated in buffer C (20 mM
estimated as a consequence of the annelated thiophene Tris/HCl, pH 7.4, 50 mM NaCl) and concentrated to 8 mg ml1. Prior
ring. The common pyrimidine-dione substructure docks to crystallization, 5 mM TPI (Taiho Pharmaceutical Co. Ltd., Japan)
in a similar manner for all the ligands and the estimated was added to the protein and incubated at 4C for 30 min. The HTP-
TPI complex was crystallized at 15C using the hanging-drop vaporaffinities are correctly ranked in comparison to the ex-
diffusion method by mixing equal volumes of complex solution andperimental IC50s. The estimated TPI binding affinity is
precipitant (8% PEG 1000 [w/v], 50 mM malate/imidazole, pH 6.5,poorer than expected and we have examined the effect
100 mM MgCl2). Crystals grew in some wells only and reached theirof introducing phosphate into the binding site. This gives full size after approximately 3 weeks. Crystals were harvested into
rise to an enhanced calculated affinity for TPI (0.5 nM) cryoprotectant solution (9% PEG 1000, 50 mM malate/imidazole,
and IV (200 nM) but is deleterious to the binding of the pH 6.5, 100 mM MgCl2, 20% [v/v] glycerol) and flash cooled in a
nitrogen stream at 100 K.anions II (14 mM) and III (4 mM), probably due to the
electrostatic repulsion between like charges. We know
from the structure that phosphate binding, although Structure Determination and Refinement
HTP diffraction data were collected from a single crystal at 100 Kmandatory for the enzyme mechanism, is not a neces-
on an ADSC CCD detector on beamline 14-2 at the SRS (Daresbury,sary requirement for inhibitor binding. These studies
UK) and processed with MOSFLM and SCALA (CCP4, 1994; Leslie,indicate that the HTP structure can be used to predict
1992). Diffraction data extends to 2.1 A˚, but the data are essentially
docking modes and relative binding affinities for candi- complete only to 2.7 A˚. Statistics for the data collection are given
date inhibitors of HTP. In addition, the probable ionic in Table 1. The structure was solved by the molecular replacement
method using a modification (nonconserved residues truncated tostatus of the bound form of the ligand can be suggested.
alanine or glycine; ligand and water molecules excluded) of theStructure-based design studies to date have been
crystal structure of BsPYNP (PDB code 1brw, chain B) as a searchimpeded by the lack of an HTP structure and the limita-
model. Rotation and translation searches were carried out usingtions of homology models based on bacterial structures.
the program AMORE (CCP4, 1994). The statistically most promising
An active conformation of the enzyme is needed for solution was eventually proven correct, though it was with consider-
these studies and the structure of HTP bound to an able difficulty that sufficient clarity and connectivity could be ob-
tained in the first derived electron density maps to allow rebuildinginhibitor shows that this can be achieved in the absence
Figure 7. Inhibitor Design
Orthogonal views of the HTP active site with
bound TPI (light purple). Van der Waals radii
for bound water molecules are shown (red),
highlighting the available space exploitable
in drug design.
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